首页 | 本学科首页   官方微博 | 高级检索  
检索        

无色素性恶性黑色素瘤的免疫组化研究
引用本文:王丽霞,畅俊平.无色素性恶性黑色素瘤的免疫组化研究[J].肿瘤研究与临床,1999,11(3):173-174.
作者姓名:王丽霞  畅俊平
作者单位:山西省肿瘤医院
摘    要:目的探讨免疫组化在无色素性恶性黑色素瘤诊断和鉴别诊断的应用价值。方法回顾分析37例可疑无色素性恶性黑色素瘤的组织学特点并进行免疫组化研究。结果37例中16例HMB45、S-100和Vimentin阳性,证实为恶性黑色素瘤;21例HMB45阴性,阴性者中7例cytokeratin和CEA、EMA阳性,诊断为癌;8例LCA阳性,诊断为淋巴瘤,6例Vimentin等阳性,诊断为肉瘤。结论HMB45和S-100是无色素性恶性黑色素瘤的诊断性标记物,前者更具特异性。HMB45联合其它相关抗体可以作为无色素性恶黑鉴别诊断指标。

关 键 词:恶性黑色素瘤  免疫组化  诊断  鉴别诊断

IMMUNOHISTOCHEMISTRY STUDY ON AMELANOTIC MALIGNANT MELANOMA
Wang Lixia,Chang Junping,Sun Yafei,et al BXShanxi Tumour Hospital.IMMUNOHISTOCHEMISTRY STUDY ON AMELANOTIC MALIGNANT MELANOMA[J].Cancer Research and Clinic,1999,11(3):173-174.
Authors:Wang Lixia  Chang Junping  Sun Yafei  BXShanxi Tumour Hospital
Abstract:Objective To study the immunohistochemical value in diagnosis and differential diagnosis of amelanotic malignant melanoma. Methods To review the histological and immunohistochemical character istic in amelanotic malignant melanoma. Results 16 of 37 cases were confirmed with amelanotic malignant melanoma by HMB45 and S100 or Vimentin.7 of 37 cases were carcinoma with HMB45, Cytokeratin ,CEA ,EMA .8 of 27 cases were lymphoma with LCA . Other 6 cases were sarcoma with Vimentin . Conclusion HMB45 and S100 were diagnostic marker of malignant melanoma. HMB45 is more specific than other antibodies. HMB45 with other antibodies can be a differential diagnostic marker in amelanotic malignant melanoma.
Keywords:Malignant melanomaImmunohistochemistryDifferential diagnosis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号